RxDoctor Payments Data

Andrew Whittington, DO

Internal Medicine · Oxford, MSNPI 1427406362

Payments from drug & device makers

$529in general payments, 2019–2025

Across 26 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$155
  • Johnson & Johnson$66
  • Nevro Corp.$47
  • Novartis$44
  • Electromed, Inc.$34
  • Boston Scientific$28
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$529 in reported general payments places this provider in the 50th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$136,929
Medicare patients
649
Services billed
2,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$35,153
CreonLipase/Protease/Amylase13$31,679
EliquisApixaban33$27,873
JardianceEmpagliflozin16$22,818
XareltoRivaroxaban13$20,487
FarxigaDapagliflozin Propanediol19$17,477
GlyxambiEmpagliflozin/Linagliptin20$13,069
JanuviaSitagliptin Phosphate17$12,095
MounjaroTirzepatide11$11,498
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,821
MyrbetriqMirabegron17$7,348
FiaspInsulin Aspart (Niacinamide)11$3,592
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid16$2,221
Potassium Chloride53$1,000
Gabapentin83$894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp$19$38,74545 claims
Boehringer IngelheimJardiance, Glyxambi$155$35,88836 claims
PfizerEliquis$17$27,87333 claims
Johnson & JohnsonXarelto$66$20,48713 claims
AstraZenecaFarxiga$13$17,47719 claims
Lilly USA, LLCMounjaro$16$11,49811 claims
GSKTrelegy Ellipta$28$10,82117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →